Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

1.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C.

Ann Oncol. 2014 Apr 29. [Epub ahead of print]

PMID:
24608200
[PubMed - as supplied by publisher]
2.

Why your preferred targeted drugs may become unaffordable.

Piccart MJ.

Cancer Res. 2013 Oct 1;73(19):5849-51. doi: 10.1158/0008-5472.CAN-13-1486. Epub 2013 Sep 23. Review.

PMID:
24062313
[PubMed - indexed for MEDLINE]
3.

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C.

J Natl Cancer Inst. 2013 Jul 3;105(13):960-7. doi: 10.1093/jnci/djt121. Epub 2013 Jun 5.

PMID:
23739063
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C.

J Clin Oncol. 2013 Mar 1;31(7):860-7. doi: 10.1200/JCO.2011.41.0902. Epub 2013 Jan 22.

PMID:
23341518
[PubMed - indexed for MEDLINE]
5.

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ, Sotiriou C.

PLoS One. 2013;8(1):e53292. doi: 10.1371/journal.pone.0053292. Epub 2013 Jan 2.

PMID:
23301057
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA.

J Clin Oncol. 2013 Jan 1;31(1):73-9. doi: 10.1200/JCO.2012.44.2285. Epub 2012 Nov 19.

PMID:
23169515
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.

Piccart MJ.

Ann Oncol. 2012 Aug;23 Suppl 6:vi5-6. No abstract available.

PMID:
23012303
[PubMed - indexed for MEDLINE]
Free Article
8.

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.

Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S.

Clin Cancer Res. 2012 Mar 1;18(5):1341-51. doi: 10.1158/1078-0432.CCR-11-2599. Epub 2012 Jan 18.

PMID:
22261811
[PubMed - indexed for MEDLINE]
Free Article
9.

A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future.

Sledge GW, Cardoso F, Winer EP, Piccart MJ.

Am Soc Clin Oncol Educ Book. 2012:28-38. doi: 10.14694/EdBook_AM.2012.32.28.

PMID:
24451704
[PubMed - in process]
Free Article
10.

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart MJ, Sotiriou C.

Endocr Relat Cancer. 2011 Nov 14;18(6):721-30. doi: 10.1530/ERC-11-0180. Print 2011 Dec.

PMID:
21984694
[PubMed - indexed for MEDLINE]
Free Article
11.

HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

Loi S, de Azambuja E, Pugliano L, Sotiriou C, Piccart MJ.

Curr Opin Oncol. 2011 Nov;23(6):547-58. doi: 10.1097/CCO.0b013e32834bd4c9. Review.

PMID:
21918439
[PubMed - indexed for MEDLINE]
12.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.

PMID:
21917518
[PubMed - indexed for MEDLINE]
Free Article
13.

Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

Bozovic-Spasojevic I, Azim HA Jr, Paesmans M, Suter T, Piccart MJ, de Azambuja E.

Lancet Oncol. 2011 Mar;12(3):209-11. doi: 10.1016/S1470-2045(11)70013-4. Epub 2011 Feb 25. No abstract available.

PMID:
21354372
[PubMed - indexed for MEDLINE]
14.

Motherhood after breast cancer: searching for la dolce vita.

Azim HA Jr, Peccatori FA, de Azambuja E, Piccart MJ.

Expert Rev Anticancer Ther. 2011 Feb;11(2):287-98. doi: 10.1586/era.10.208. Review.

PMID:
21342046
[PubMed - indexed for MEDLINE]
15.

Long-term toxic effects of adjuvant chemotherapy in breast cancer.

Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ.

Ann Oncol. 2011 Sep;22(9):1939-47. doi: 10.1093/annonc/mdq683. Epub 2011 Feb 2. Review.

PMID:
21289366
[PubMed - indexed for MEDLINE]
Free Article
16.

Pattern of care in locally advanced breast cancer: focus on local therapy.

Sinacki M, Badzio A, Wełnicka-Jaśkiewicz M, Bogaerts J, Piccart MJ, Therasse P, Smith IE, Hatschek T, Jassem J.

Breast. 2011 Apr;20(2):145-50. doi: 10.1016/j.breast.2010.08.008. Epub 2010 Sep 25.

PMID:
20870406
[PubMed - indexed for MEDLINE]
17.

Simultaneous targeting of estrogen receptor and HER2 in breast cancer.

Azim HA Jr, Piccart MJ.

Expert Rev Anticancer Ther. 2010 Aug;10(8):1255-63. doi: 10.1586/era.10.99. Review.

PMID:
20735311
[PubMed - indexed for MEDLINE]
18.

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10208-13. doi: 10.1073/pnas.0907011107. Epub 2010 May 17.

PMID:
20479250
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer.

Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ, Speed TP, McArthur GA.

BMC Med Genomics. 2009 Jun 24;2:37. doi: 10.1186/1755-8794-2-37.

PMID:
19552798
[PubMed]
Free PMC Article
20.

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P.

J Clin Oncol. 2008 Oct 20;26(30):4883-90. doi: 10.1200/JCO.2007.14.4659. Epub 2008 Sep 15.

PMID:
18794551
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk